Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
Authors:
- Francesco PassigliaFPFrancesco Passiglia
- Antonio GalvanoAGAntonio Galvano
- Valerio GristinaVGValerio Gristina
- Nadia BarracoNBNadia Barraco
- Marta CastigliaMCMarta Castiglia
- Alessandro PerezAPAlessandro Perez
- Maria La MantiaMMMaria La Mantia
- Antonio RussoAntonio Russo
- Viviana BazanVBViviana Bazan
Open Access
- 1 July 2021
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 10 (7) , 3106-3119
Abstract
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups Francesco Passiglia, Antonio Galvano, Valerio Gristina, Nadia Barraco, Marta Castiglia, Alessandro Perez, Maria La Mantia, Antonio Russo, Viviana BazanKeywords
This publication has 17 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2019
- Rational application of the first‐line chemotherapy and immune checkpoint inhibitors in advanced nonsmall cell lung cancer: A meta‐analysisCancer Medicine, 2019
- Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trialThe Lancet Oncology, 2019
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trialThe Lancet, 2019
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLCNew England Journal of Medicine, 2018
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational BurdenNew England Journal of Medicine, 2018
- Pembrolizumab as First-Line Therapy for Metastatic Non-Small-Cell Lung CancerImmunotherapy, 2017
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Indirect comparisons of competing interventionsHealth Technology Assessment, 2005
- Network meta‐analysis for indirect treatment comparisonsStatistics in Medicine, 2002